Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9819832 | 0.88 | MEN1 (0.68) | ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10 | |
| SCHEMBL15569567 | 0.88 | HRH2 (0.50) | ALDH1A1POLBSMN1; SMN2LMNAMEN1 | |
| SCHEMBL11093397 | 0.87 | DRD2 (0.70) | ALDH1A1KDM4EPOLBSMN1; SMN2LMNA | |
| SCHEMBL3911272 | 0.86 | POLB (0.50) | ALDH1A1POLBSMN1; SMN2LMNAHRH3 | |
| SCHEMBL7475308 | 0.85 | ALDH1A1 (0.70) | ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10 | |
| Bromide SCHEMBL11338873 | 0.84 | ALDH1A1 (0.63) | ALDH1A1KDM4EPOLBHSD17B10ALOX15 | |
| SCHEMBL2652152 | 0.83 | ALDH1A1 (0.59) | ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10 | |
| SCHEMBL265853 | 0.83 | VEGFA (0.55) | ALDH1A1SMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL29754386 | 0.82 | DRD2 (0.53) | ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10 | |
| SCHEMBL26448072 | 0.82 | DRD2 (0.53) | ALDH1A1KDM4EPOLBSMN1; SMN2HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605154-B2 | ATP-protein kinase inhibitors; cytomegalovirus; contraceptive agents; cancer; N7-(3-ethynyl-phenyl)-N2-(4-piperidin-1-ylmethyl-phenyl)-thiazolo[4,5-d]pyrimidine-2,7-diamine | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-20 | — | — | US | disclosed |
| EP-1912639-A2 | THIAZOLOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-23 | — | — | EP | disclosed |
| US-20070185139-A1 | Thiazolopyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-09 | — | — | US | disclosed |
| WO-2007019191-A2 | THIAZOLOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185139-A1 | Thiazolopyrimidine kinase inhibitors | ABL1, MAP3K19, PI4KB | ALDH1A1 2812/4885KDM4E 2426/4885POLB 1150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.